ATE430568T1 - Verfahren und zusammensetzungen zur vorbeugung oder behandlung von atherosclerose, restenose und zusammenhängenden erkrankungen - Google Patents

Verfahren und zusammensetzungen zur vorbeugung oder behandlung von atherosclerose, restenose und zusammenhängenden erkrankungen

Info

Publication number: ATE430568T1
Authority: AT; Austria
Prior art keywords: restenosis; compositions; methods; preventing; related diseases
Prior art date: 1999-12-15

Application number

AT00984269T

Other languages

English (en)

Inventor

Jerome Zeldis

Original Assignee

Celgene Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-12-15

Filing date

2000-12-13

Publication date

2009-05-15

2000-12-13 Application filed by Celgene Corp filed Critical Celgene Corp

2009-05-15 Application granted granted Critical

2009-05-15 Publication of ATE430568T1 publication Critical patent/ATE430568T1/de

Links

201000001320 Atherosclerosis Diseases 0.000 title abstract 2
238000000034 method Methods 0.000 title abstract 2
239000000203 mixture Substances 0.000 title abstract 2
208000037803 restenosis Diseases 0.000 title abstract 2
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
230000002265 prevention Effects 0.000 abstract 2
UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 abstract 1
108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
239000011248 coating agent Substances 0.000 abstract 1
238000000576 coating method Methods 0.000 abstract 1
230000007062 hydrolysis Effects 0.000 abstract 1
238000006460 hydrolysis reaction Methods 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
239000002207 metabolite Substances 0.000 abstract 1
239000002243 precursor Substances 0.000 abstract 1
-1 thalidomide Chemical class 0.000 abstract 1
229960003433 thalidomide Drugs 0.000 abstract 1
102000003390 tumor necrosis factor Human genes 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Cardiology (AREA)
Obesity (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Biophysics (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Child & Adolescent Psychology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Vascular Medicine (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Materials For Medical Uses (AREA)

AT00984269T 1999-12-15 2000-12-13 Verfahren und zusammensetzungen zur vorbeugung oder behandlung von atherosclerose, restenose und zusammenhängenden erkrankungen ATE430568T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US17082099P	1999-12-15	1999-12-15
PCT/US2000/033708 WO2001043743A1 (en)	1999-12-15	2000-12-13	Methods and compositions for the prevention and treatment of atherosclerosis, restenosis and related disorders

Publications (1)

Publication Number	Publication Date
ATE430568T1 true ATE430568T1 (de)	2009-05-15

Family

ID=22621397

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00984269T ATE430568T1 (de)	1999-12-15	2000-12-13	Verfahren und zusammensetzungen zur vorbeugung oder behandlung von atherosclerose, restenose und zusammenhängenden erkrankungen

Country Status (10)

Country	Link
US (3)	US7182953B2 (de)
EP (2)	EP2016942A1 (de)
JP (1)	JP2003517012A (de)
AT (1)	ATE430568T1 (de)
AU (1)	AU782753B2 (de)
CA (1)	CA2395474A1 (de)
DE (1)	DE60042172D1 (de)
ES (1)	ES2326359T3 (de)
HK (1)	HK1051316B (de)
WO (1)	WO2001043743A1 (de)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5635517B1 (en) *	1996-07-24	1999-06-29	Celgene Corp	Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
HU228769B1 (en) *	1996-07-24	2013-05-28	Celgene Corp	Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US7629360B2 (en) *	1999-05-07	2009-12-08	Celgene Corporation	Methods for the treatment of cachexia and graft v. host disease
US6458810B1 (en)	2000-11-14	2002-10-01	George Muller	Pharmaceutically active isoindoline derivatives
ATE374609T1 (de) *	2000-11-30	2007-10-15	Childrens Medical Center	Synthese von 4-aminothalidomid enantiomeren
JP3990972B2 (ja) *	2001-11-20	2007-10-17	有限会社キック	血管再狭窄防止薬及び該防止薬がコーティングされた血管内埋め込み器具
US7498171B2 (en) *	2002-04-12	2009-03-03	Anthrogenesis Corporation	Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US7323479B2 (en) *	2002-05-17	2008-01-29	Celgene Corporation	Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
USRE48890E1 (en)	2002-05-17	2022-01-11	Celgene Corporation	Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
US7393862B2 (en)	2002-05-17	2008-07-01	Celgene Corporation	Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US20100129363A1 (en) *	2002-05-17	2010-05-27	Zeldis Jerome B	Methods and compositions using pde4 inhibitors for the treatment and management of cancers
EP2258363A1 (de) *	2002-05-17	2010-12-08	Celgene Corporation	Zusammensetzungen zur Behandlung von Krebs
US7968569B2 (en)	2002-05-17	2011-06-28	Celgene Corporation	Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US8404717B2 (en) *	2002-10-15	2013-03-26	Celgene Corporation	Methods of treating myelodysplastic syndromes using lenalidomide
US11116782B2 (en)	2002-10-15	2021-09-14	Celgene Corporation	Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404716B2 (en) *	2002-10-15	2013-03-26	Celgene Corporation	Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7189740B2 (en) *	2002-10-15	2007-03-13	Celgene Corporation	Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
CN1713905A (zh) *	2002-10-15	2005-12-28	细胞基因公司	用于治疗骨髓增生异常综合征的选择性细胞因子抑制药
US20050203142A1 (en) *	2002-10-24	2005-09-15	Zeldis Jerome B.	Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
AU2003286660A1 (en) *	2002-10-25	2004-05-13	Essentia Biosystems, Inc.	Implantable medical devices using zinc
US20040091455A1 (en) *	2002-10-31	2004-05-13	Zeldis Jerome B.	Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
TW200501945A (en)	2002-11-06	2005-01-16	Celgene Corp	Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
US7563810B2 (en) *	2002-11-06	2009-07-21	Celgene Corporation	Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) *	2002-11-06	2011-10-11	Celgene Corporation	Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US20040175382A1 (en) *	2003-03-06	2004-09-09	Schafer Peter H.	Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
UA83504C2 (en)	2003-09-04	2008-07-25	Селджин Корпорейшн	Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20080027113A1 (en) *	2003-09-23	2008-01-31	Zeldis Jerome B	Methods of Using and Compositions Comprising Immunomodulatory Compounds for Treatment and Management of Macular Degeneration
US7612096B2 (en) *	2003-10-23	2009-11-03	Celgene Corporation	Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
US20050100529A1 (en) *	2003-11-06	2005-05-12	Zeldis Jerome B.	Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
KR20060124607A (ko) *	2003-11-06	2006-12-05	셀진 코포레이션	암 및 그 밖의 질환의 치료 및 관리를 위하여탈리도마이드를 사용하는 방법 및 조성물
US20050182097A1 (en) *	2003-12-30	2005-08-18	Zeldis Jerome B.	Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases
US20050143344A1 (en) *	2003-12-30	2005-06-30	Zeldis Jerome B.	Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
CA2560221C (en) *	2004-03-22	2010-12-07	Celgene Corporation	Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
US20050222209A1 (en) *	2004-04-01	2005-10-06	Zeldis Jerome B	Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
US20050228473A1 (en) *	2004-04-05	2005-10-13	David Brown	Device and method for delivering a treatment to an artery
AU2004319758A1 (en) *	2004-04-14	2005-11-24	Celgene Corporation	Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
US20080213213A1 (en) *	2004-04-14	2008-09-04	Zeldis Jerome B	Method For the Treatment of Myelodysplastic Syndromes Using (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione
BRPI0510167A (pt) *	2004-04-23	2007-10-02	Celgene Corp	método para tratar, prevenir ou controlar hipertensão pulmonar
US20050239842A1 (en) *	2004-04-23	2005-10-27	Zeldis Jerome B	Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
US20050267556A1 (en) *	2004-05-28	2005-12-01	Allan Shuros	Drug eluting implants to prevent cardiac apoptosis
WO2006019204A1 (en) *	2004-08-16	2006-02-23	Seoul National University Industry Foundation	Pharmaceutical composition for treating and preventing artery restenosis containing thalidomide
US20070190070A1 (en) *	2004-09-03	2007-08-16	Zeldis Jerome B	Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
US20060099235A1 (en) *	2004-11-11	2006-05-11	Medtronic Vascular, Inc.	Medical devices and compositions useful for treating or inhibiting restenosis
ZA200704890B (en) *	2004-11-23	2008-09-25	Celgene Corp	Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
US20060270707A1 (en) *	2005-05-24	2006-11-30	Zeldis Jerome B	Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
MX2007016290A (es)	2005-06-30	2008-03-10	Celgene Corp	Procesos para la preparacion de compuestos de 4-amino-2(2,6-dioxopiperidin-3-il)isoindolin-1,3-diona.
UA91560C2 (ru)	2005-08-31	2010-08-10	Селджин Корпорэйшн	Соединения ряда изоиндолимидов, их композиция и применение
US20080138295A1 (en) *	2005-09-12	2008-06-12	Celgene Coporation	Bechet's disease using cyclopropyl-N-carboxamide
US20070155791A1 (en) *	2005-12-29	2007-07-05	Zeldis Jerome B	Methods for treating cutaneous lupus using aminoisoindoline compounds
US20080064876A1 (en) *	2006-05-16	2008-03-13	Muller George W	Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
CL2007002218A1 (es) *	2006-08-03	2008-03-14	Celgene Corp Soc Organizada Ba	Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
US8877780B2 (en)	2006-08-30	2014-11-04	Celgene Corporation	5-substituted isoindoline compounds
DE102006042313A1 (de) *	2006-09-06	2008-03-27	Biotronik Vi Patent Ag	Biokorrodierbares metallisches Implantat mit einer Beschichtung oder Kavitätenfüllung aus Gelatine
ME02420B (me)	2006-09-26	2016-09-20	Celgene Corp	5-supstituirani derivati kinazolinona kao sredstva protiv raka
AP2009004834A0 (en) *	2006-10-19	2009-04-30	Celgene Corp	Methods and compositions using immunomodulatory c ompounds for the treatment and management of spirochete and other obligate intracellular bacterial diseases
US7893045B2 (en)	2007-08-07	2011-02-22	Celgene Corporation	Methods for treating lymphomas in certain patient populations and screening patients for said therapy
CA2704710C (en)	2007-09-26	2016-02-02	Celgene Corporation	6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising the same
WO2009061445A2 (en) *	2007-11-08	2009-05-14	Celgene Corporation	Use of immunomodulatory compounds for the treatment of disorders associated with endothelial dysfunction
US20090298882A1 (en) *	2008-05-13	2009-12-03	Muller George W	Thioxoisoindoline compounds and compositions comprising and methods of using the same
PT2358697E (pt)	2008-10-29	2016-02-03	Celgene Corp	Compostos de isoindolina para utilização no tratamento do cancro
US20120053159A1 (en)	2009-02-11	2012-03-01	Muller George W	Isotopologues of lenalidomide
BRPI1007855B1 (pt)	2009-05-19	2020-03-10	Celgene Corporation	Formas de dosagem oral compreendendo 4-amino-2-(2,6-dioxopiperidina-3-il)isoindolina-1,3-diona
BR112012015129A2 (pt)	2009-12-22	2019-09-24	Celgene Corp	"composto, composição farmacêutica e método para tratar, controlar ou prevenir uma doença ou distúrbio"
PL3202460T3 (pl)	2010-02-11	2019-12-31	Celgene Corporation	Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania
EP2663549B1 (de)	2011-01-10	2018-03-14	Celgene Corporation	Phenethylsulfonisoindolinderivate als pde-4- und/oder zytokin-hemmer
DK2683708T3 (da)	2011-03-11	2018-01-29	Celgene Corp	Faste former af 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidin-2,6-dion og farmaceutiske sammensætninger og anvendelser deraf
EP2699091B1 (de)	2011-03-28	2017-06-21	DeuteRx, LLC	2',6'-dioxo-3'-deutero-piperidin-3-yl-isoindolin-verbindungen
US20140221427A1 (en)	2011-06-22	2014-08-07	Celgene Corporation	Isotopologues of pomalidomide
RU2627471C2 (ru)	2011-09-14	2017-08-08	Селджин Корпорейшн	Препараты { 2-[(1s)-1-(3-этокси-4-метоксифенил)-2-метансульфонилэтил]-3-оксо-2,3-дигидро-1h-изоиндол-4-ил} амида циклопропанкарбоновой кислоты
RS60415B1 (sr)	2011-12-27	2020-07-31	Amgen (Europe) GmbH	Formulacije (+)-2-[1-(3-etoksi-4-metoksi-fenil)-2-metansulfonil-etil]-4-acetil aminoizoindolin-1,3-diona
WO2013149250A1 (en) *	2012-03-30	2013-10-03	The Regents Of The University Of California	Methods of treatment, diagnosis and monitoring for methamphetamine toxicity which target ceramide metabolic pathways and cellular senescence
JP6359563B2 (ja)	2013-01-14	2018-07-18	デュートルクス・リミテッド・ライアビリティ・カンパニーＤｅｕｔｅＲｘ，ＬＬＣ	３−（５置換−４−オキソキナゾリン−３（４ｈ）−イル）−３−ジュウテロピペリジン−２，６−ジオン誘導体
EP2764866A1 (de)	2013-02-07	2014-08-13	IP Gesellschaft für Management mbH	Hemmer der nedd8-aktivierenden Enzyme
EP3046627B1 (de)	2013-09-18	2019-10-23	The Board of Trustees of the Leland Stanford Junior University	Modulation der efferozytose-signalwege zur behandlung einer atherosklerotischen erkrankung
WO2015175956A1 (en) *	2014-05-16	2015-11-19	Celgene Corporation	Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
AU2015305449B2 (en)	2014-08-22	2021-05-06	Celgene Corporation	Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
WO2016138306A1 (en)	2015-02-27	2016-09-01	The Board Of Trustees Of The Leland Stanford Junior University	Combination therapy for treatment of coronary artery disease
HUE065109T2 (hu)	2015-06-26	2024-05-28	Celgene Corp	Eljárások Kaposi-szarkóma vagy KSHV-indukált limfóma kezelésére immunomodulátor vegyületek alkalmazásával, valamint biomarkerek alkalmazása
US10093647B1 (en)	2017-05-26	2018-10-09	Celgene Corporation	Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate, compositions and methods of use thereof
US10093649B1 (en)	2017-09-22	2018-10-09	Celgene Corporation	Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof
US10093648B1 (en)	2017-09-22	2018-10-09	Celgene Corporation	Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof
US10537585B2 (en)	2017-12-18	2020-01-21	Dexcel Pharma Technologies Ltd.	Compositions comprising dexamethasone
TW202000646A (zh)	2018-03-07	2020-01-01	瑞士商西建國際第二有限責任公司	用於治療癌症、潰瘍性結腸炎及相關發炎疾病之異吲哚啉-1,3-二酮之組合物及方法及異吲哚前藥

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3536809A (en)	1969-02-17	1970-10-27	Alza Corp	Medication method
US3598123A (en)	1969-04-01	1971-08-10	Alza Corp	Bandage for administering drugs
US3845770A (en)	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US3916899A (en)	1973-04-25	1975-11-04	Alza Corp	Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en)	1976-02-02	1977-02-22	Alza Corporation	Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en)	1984-10-30	1993-07-14	Elan Corp Plc	Controlled release powder and process for its preparation
US5073543A (en)	1988-07-21	1991-12-17	G. D. Searle & Co.	Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it)	1989-03-22	1991-07-25	Bioresearch Spa	Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en)	1989-11-07	1992-06-09	Merck & Co., Inc.	Swelling modulated polymeric drug delivery device
US5733566A (en)	1990-05-15	1998-03-31	Alkermes Controlled Therapeutics Inc. Ii	Controlled release of antiparasitic agents in animals
US5580578A (en)	1992-01-27	1996-12-03	Euro-Celtique, S.A.	Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en)	1993-01-25	1997-01-07	Pharmetrix Corporation	Liquid reservoir transdermal patch for the administration of ketorolac
US5629327A (en)	1993-03-01	1997-05-13	Childrens Hospital Medical Center Corp.	Methods and compositions for inhibition of angiogenesis
US5698579A (en)	1993-07-02	1997-12-16	Celgene Corporation	Cyclic amides
US5605914A (en)	1993-07-02	1997-02-25	Celgene Corporation	Imides
US5849736A (en)	1993-11-24	1998-12-15	The Dupont Merck Pharmaceutical Company	Isoxazoline and isoxazole fibrinogen receptor antagonists
DE4422237A1 (de)	1994-06-24	1996-01-04	Gruenenthal Gmbh	Verwendung von Lactamverbindungen als pharmazeutische Wirkstoffe
IT1270594B (it)	1994-07-07	1997-05-07	Recordati Chem Pharm	Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
CZ288436B6 (en)	1994-10-05	2001-06-13	Darwin Discovery Ltd	Peptidyl derivatives, their therapeutic use as inhibitors of metalloproteinases and pharmaceutical preparation in which they are comprised
US5637113A (en)	1994-12-13	1997-06-10	Advanced Cardiovascular Systems, Inc.	Polymer film for wrapping a stent structure
US5801195A (en)	1994-12-30	1998-09-01	Celgene Corporation	Immunotherapeutic aryl amides
US5703098A (en)	1994-12-30	1997-12-30	Celgene Corporation	Immunotherapeutic imides/amides
US5837313A (en)	1995-04-19	1998-11-17	Schneider (Usa) Inc	Drug release stent coating process
US5728844A (en)	1995-08-29	1998-03-17	Celgene Corporation	Immunotherapeutic agents
US5728845A (en)	1995-08-29	1998-03-17	Celgene Corporation	Immunotherapeutic nitriles
US5658940A (en)	1995-10-06	1997-08-19	Celgene Corporation	Succinimide and maleimide cytokine inhibitors
US5948786A (en) *	1996-04-12	1999-09-07	Sumitomo Pharmaceuticals Company, Limited	Piperidinylpyrimidine derivatives
ATE322900T1 (de) *	1996-07-15	2006-04-15	Macrozyme Dnm B V	Deoxynojirimycin derivate und ihre verwendung als glukosesylceramidase-inhibitoren
US5635517B1 (en) *	1996-07-24	1999-06-29	Celgene Corp	Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
DE122007000079I2 (de) *	1996-07-24	2010-08-12	Celgene Corp	Substituierte 2-(2,6-dioxopiperidin-3-yl)-phthalimide und -1-oxoisoindoline und verfahren zur reduzierung des tnf-alpha-spiegels
US5798368A (en)	1996-08-22	1998-08-25	Celgene Corporation	Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
NZ334148A (en)	1996-08-12	2001-12-21	Celgene Corp	3-Substituted phenyl-ethyl or ethenyl derivatives terminated with a nitrile, alkane, carboxyl or carbamoyl group useful to reduce cytokine levels
JP2002511052A (ja)	1996-08-29	2002-04-09	メルクエンドカンパニーインコーポレーテッド	インテグリンアンタゴニスト
HUP0003761A3 (en)	1997-07-31	2001-04-28	Celgene Corp Warren	Substituted alkanohydroxamic acids and pharmaceutical compositions containing them
US5874448A (en)	1997-11-18	1999-02-23	Celgene Corporation	Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
EP1054647B1 (de) *	1998-02-12	2005-12-21	Thomas R. Marotta	Endovaskuläre prothese
AU749356B2 (en)	1998-05-11	2002-06-27	Children's Medical Center Corporation	Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis
WO2000010552A2 (en)	1998-08-24	2000-03-02	Global Vascular Concepts, Inc.	Use of anti-angiogenic agents for inhibiting vessel wall injury
US6020358A (en)	1998-10-30	2000-02-01	Celgene Corporation	Substituted phenethylsulfones and method of reducing TNFα levels

2000
- 2000-12-11 US US09/734,460 patent/US7182953B2/en not_active Expired - Fee Related
- 2000-12-13 JP JP2001544881A patent/JP2003517012A/ja active Pending
- 2000-12-13 AU AU20916/01A patent/AU782753B2/en not_active Ceased
- 2000-12-13 HK HK03102043.0A patent/HK1051316B/en not_active IP Right Cessation
- 2000-12-13 EP EP08163144A patent/EP2016942A1/de not_active Withdrawn
- 2000-12-13 ES ES00984269T patent/ES2326359T3/es not_active Expired - Lifetime
- 2000-12-13 EP EP00984269A patent/EP1242082B1/de not_active Expired - Lifetime
- 2000-12-13 AT AT00984269T patent/ATE430568T1/de not_active IP Right Cessation
- 2000-12-13 DE DE60042172T patent/DE60042172D1/de not_active Expired - Lifetime
- 2000-12-13 CA CA002395474A patent/CA2395474A1/en not_active Abandoned
- 2000-12-13 WO PCT/US2000/033708 patent/WO2001043743A1/en not_active Ceased
2005
- 2005-08-30 US US11/216,950 patent/US7325355B2/en not_active Expired - Fee Related
2007
- 2007-12-07 US US12/001,036 patent/US20080096952A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HK1051316B (en)	2009-08-21
WO2001043743A1 (en)	2001-06-21
CA2395474A1 (en)	2001-06-21
HK1051316A1 (en)	2003-08-01
EP1242082A1 (de)	2002-09-25
DE60042172D1 (de)	2009-06-18
EP1242082B1 (de)	2009-05-06
US7182953B2 (en)	2007-02-27
US20080096952A1 (en)	2008-04-24
JP2003517012A (ja)	2003-05-20
EP2016942A1 (de)	2009-01-21
AU2091601A (en)	2001-06-25
US20060004054A1 (en)	2006-01-05
US20020054899A1 (en)	2002-05-09
US7325355B2 (en)	2008-02-05
AU782753B2 (en)	2005-08-25
ES2326359T3 (es)	2009-10-08

Legal Events

Date	Code	Title	Description
2009-11-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE430568T1 (de)	2009-05-15	Verfahren und zusammensetzungen zur vorbeugung oder behandlung von atherosclerose, restenose und zusammenhängenden erkrankungen
DE69422450D1 (de)	2000-02-10	Chinoline oder Chinazolin-Derivate und deren Verwendung zur Herstellung eines Medikaments für die Behandlung von Osteoporose
IL144144A0 (en)	2002-05-23	Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
SE9901272D0 (sv)	1999-04-09	New improved formulation
ATE399547T1 (de)	2008-07-15	Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und vorbeugung von neoplasia
DE69805973D1 (de)	2002-07-18	Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
DE69828042D1 (de)	2005-01-13	Verfahren und zusammensetzung zur behandlung von krebs
MY141661A (en)	2010-05-31	17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
DK1274692T3 (da)	2006-10-30	Quinazolinforbindelser
ATE358668T1 (de)	2007-04-15	Drogen zur behandlung maligner tumoren
WO2001030333A3 (en)	2002-02-07	Tissue factor antagonists and methods of use thereof
ATE198706T1 (de)	2001-02-15	Polyamin-verbindungen zur behandlung von proliferativer erkrankungen
ATE362374T1 (de)	2007-06-15	Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
ATE260282T1 (de)	2004-03-15	Aromatische ester von camptothecinen und verfahren zur behandlung von krebserkrankungen
ATE260653T1 (de)	2004-03-15	Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
MXPA04003611A (es)	2004-07-30	Piperidina- y piperazinacetaminas como inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
ATE141051T1 (de)	1996-08-15	Verwendung von melatonin zur herstellung eines arzneimittels zur behandlung der gutartigen prostatahyperplasie
DE3854121D1 (de)	1995-08-10	Arzneimittelzusammensetzungen zur behandlung von psoriasis.
DE60018704D1 (de)	2005-04-21	Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE69805305D1 (de)	2002-06-13	Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE69917074D1 (de)	2004-06-09	Optisch aktives pyridyl-4h-1,2,4-oxadiazinderivat und seine verwendung zur behandlung von gefässkrankheiten
ATE262330T1 (de)	2004-04-15	Verwendung eines nitroxids oder seiner prodrugs zur prophylaktischen und therapeutischen behandlung von krebs
NO994041L (no)	2000-02-22	Nye indan-l-ol forbindelser, en fremgangsmÕte for Õ behandle dem og farmasøytiske forbindelser inneholdende dem
BRPI0410657A (pt)	2006-06-20	composto, composição farmacêutica, uso de um composto, método para tratar um distúrbio de um paciente, e, processo para a preparação de um composto
WO2001030334A3 (en)	2002-03-21	6-methoxy-2-naphthylacetic acid prodrugs compositions for treating inflammation